The International Neuromodulation Society

The Fastest-Growing, Worldwide Multidisciplinary Body Devoted to Building Knowledge of Neuromodulation

The International Neuromodulation Society (INS) is a non-profit group of clinicians, scientists and engineers dedicated to the scientific development and awareness of neuromodulation – the alteration of nerve activity through targeted delivery of a stimulus, such as electrical stimulation or chemical agents, to specific neurological sites in the body. The San Francisco-based INS was formed in 1989 and educates and promotes the field through meetings, its peer-reviewed journal Neuromodulation: Technology at the Neural Interface, explanatory content, and chapter websites. The INS also provides information for patients and produces rolling news briefs about this rapidly evolving field.

The INS Peer-Reviewed Journal – 8 Issues a Year

The INS journal Neuromodulation: Technology at the Neural Interface has a growing Impact Factor and is indexed in Index Medicus, MEDLINE and Pubmed from its first issue in 1998. Members may log in to the members-only section to read the journal online.

journal cover

+Submit a Manuscript.+

What is Neuromodulation?

Medical Professionals can learn about various considerations concerning neuromodulation and clinic contacts. Once your preliminary questions have been answered, please use the Contact Us facility to find out more and to discuss specific objectives. Others may simply wish to join the INS and one of its related chapter societies, please use the Membership Application.

Clinical trials that involve a wide range of emerging neuromodulation approaches are listed on our Research page. Neuromodulation clinical trials address symptom control through nerve stimulation in such condition categories as:

If you are not a medical professional and you are searching for information about neuromodulation and how these types of treatment could benefit a specific condition such as treatment-resistant headache or other chronic pain syndromes, you may find the sections titled Therapies, About Neuromodulation or FAQs particularly helpful.

Members may log in and visit the members-only section’s Global Discussion Forum

Breaking News Share

Spinal Cord Stimulator Company Announces CE Mark Approval and Commercial Launch in Europe

Sept. 16, 2019 - Saluda Medical announced CE Mark approval and commercial launch in Europe of its closed-loop spinal cord stimulation system, with the first commercial implants completed in the Netherlands. (PR Newswire)

Facility in India Has Added Noninvasive Brain Stimulation Services for Psychiatric Conditions

Sept. 13, 2019 - A tertiary care medical and research institute in Northern India has begun offering repetitive transcranial magnetic stimulation and transcranial direct current stimulation in its psychiatry department. (Hindustan Times)

Company Announces Start of Deep Brain Stimulation Study in Mild Alzheimer's Disease

Sept. 11, 2019 - Functional Neuromodulation announced it has begun a randomized, controlled trial of deep brain stimulation to the fornix in patients aged 65 or older with Alzheimer's disease. The ADvance II safety and efficacy study will enroll up to 210 patients in the United States, Canada and Germany. (Mass Device)

To see select neuromodulation news by category, as well as news about the INS in particular, please visit the Newsroom. To see archived news briefs dating back to January 2011, visit the News Archive.

Continue Reading News Briefs
Last Updated on Monday, December 12, 2016 10:01 AM